Disclaimer: The following content discusses our Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is enabled by our FDA-cleared RenovoCath. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoCath-enabled TAMP with gemcitabine for the treatment of locally advanced pancreatic cancer (LAPC) is being studied under an IND. This combination product candidate has not been approved by FDA for commercial use and its safety and effectiveness in treating LAPC has not been established. For RenovoCath’s Indications for Use and safety information, please visit IFU-10004-Rev.-G-Universal-IFU.pdf.
Released May 2, 2019
Based on results of early studies highlighted by this patient’s and other patients’ experiences, RenovoRx initiated and is currently enrolling Stage 3 pancreatic cancer patients in the TIGeR-PaC clinical trial to further test this promising new procedure for pancreatic cancer patients.
View the entire article on NBC Bay Area
* Individual results may vary.